Levo's LV-101 improves hyperphagia and behavioral symptoms in Phase II for Prader-Willi

Levo Therapeutics Inc. (Chicago, Ill.) reported data from a Phase II trial in 37 patients with genetically confirmed

Read the full 189 word article

User Sign In